Clinical trial

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

NCT05813912

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Insulin Icodec Normalized identity: insulin icodecView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Semaglutide Normalized identity: semaglutideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-09-22

PhasePHASE3

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Insulin IcodecDRUG · verified · RxNorm: insulin icodec

SemaglutideDRUG · verified · RxNorm: semaglutide

Sponsors & collaborators

Novo Nordisk A/Slead sponsor

Mapped research locations

PragueCzechia4 BangkokThailand4 GdanskPoland3 BelgradeSerbia2 WarsawPoland1 LodzPoland1 BialystokPoland1 KatowicePoland1 OlomoucCzechia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05813912 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.